All News

The Food and Drug Administration (FDA) has approved Empliciti (elotuzumab) for use in combination with Pomalyst (pomalidomide) and low-dose dexamethasone, also known as EPd, for the treatment of patients with relapsed/refractory multiple myeloma following two or more prior therapies, including Revlimid (lenalidomide) and a proteasome inhibitor.

While I am and will always be a survivor, there are times in life that it should, and will take a back seat.

Promising results from a recent trial are laying the groundwork for the first change in frontline small cell lung cancer in two decades.

When I was diagnosed with Lynch syndrome seven years ago, I began blogging about the roller coaster of emotions I experienced after undergoing genetic testing and prophylactic surgeries.

Patients with platinum-pretreated metastatic urothelial carcinoma who were treated with a higher dosage of Yervoy (ipilimumab) in combination with Opdivo (nivolumab) experienced improved survival and tolerable side effects, according to findings from the phase 1/2 CheckMate-032 trial.

The Food and Drug Administration (FDA) approved Udenyca (pegfilgrastim-cbqv), a biosimilar to Neulasta (pegfilgrastim), according to Coherus Biosciences, the biosimilar’s manufacturer.

It's more than the beard. It's about men's health.

The Food and Drug Administration (FDA) granted accelerated approval to Lorbrena (lorlatinib) for the treatment of patients with ALK-positive, metastatic non-small cell lung cancer (NSCLC) who progressed on one or more ALK tyrosine kinase inhibitor (TKI), according to Pfizer, the drug’s manufacturer.

When it comes to routine eye checkups and other appointments not directly related to my cancer, I become lax.

Here are some tips on coping with the disease that seems to affect us all.

Patients can use daily practices to help reduce stress and anxiety.

Would would happen if I turned my back to the past and faced forward? It is time to stop wishing I could go back to my pre-cancer life. It's time to face forward.

Cancer survivor encourages fellow survivors to cultivate hope to improve their survivorship time.

Here are the top 5 CURE stories for October 2018.

I may be down one ball, but I've increased in many other ways

Remembering a loved one's spirit in a new way can bring healing and hope.

The immunotherapy agent received approval for the treatment of metastatic squamous non-small cell lung cancer.

The PARP inhibitor Lynparza (olaparib) significantly improved progression-free survival (PFS) as frontline maintenance therapy for women with BRCA-positive advanced ovarian cancer, according to findings from the randomized phase 3 SOLO-1 trial presented at the 2018 ESMO Congress.

Metastatic breast cancer advocate goes to Washington DC to tell her own story and push for more research to be directed toward metastatic disease

How I battle the beast of breast cancer.

Patients can apply topical skin treatments in moderation before radiation therapy despite common advice from health care providers not to, according to study findings published in JAMA Oncology.

People with slow-growing B-cell lymphomas and no symptoms are often prescribed a watch-and-wait approach, which involves monitoring until the disease grows and warrants treatment.

Treating older patients who have Hodgkin lymphoma with Adcetris (brentuximab vedotin) before and after chemotherapy showed improved remission and survival rates, according to phase 2 study findings.

Cancer can affect all areas of life, in both good and bad ways.

The mammogram can be an emotional roller coaster for any person. After you have been diagnosed with breast cancer, even good results can tap into deep emotions.

I stepped out of my comfort zone to share my cancer story.

A cancer diagnosis can bring many fears and uncertainties to the forefront, but it can also bring friendships with people we would never have met had we not gotten cancer at all.

Though it's a weird thing to say, I'm posting this to help you realize that if you "miss having cancer," you're not the only one.

The Food and Drug Administration has granted a priority review to the supplemental new drug application for Jakafi (ruxolitinib) to treat patients with acute graft-versus-host-disease (GVHD) who have had an inadequate response to corticosteroids.

The Food and Drug Administration (FDA) has granted a priority review to a supplemental new drug application for Lonsurf (TAS-102; trifluridine/tipiracil) for use in previously treated patients with advanced or metastatic gastric adenocarcinoma, including cancer of the gastroesophageal junction.